SLC5A2 and chronic kidney disease: Results from the Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial were reported in 2021.23 While sotagliflozin is not approved for use in the USA, the SCORED trial contributes to the growing body of evidence that SGLT2 inhibitors are beneficial for cardiovascular and kidney outcomes in patients with T2D and CKD.